简介 联系方式 相互作用: 118 620
根据名称进行药物检索

Acetaminophen and Codeine Oral Solution与肝病

Acetaminophen and Codeine Oral Solution与肝病安全配伍检测的结果。

检测结果:
Acetaminophen and Codeine Oral Solution <> 肝病
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

对乙酰氨基酚是主要代谢的肝脏活的形式。 然而，小批量转换的次要代谢物的途径，可能会导致肝毒性或高铁血红蛋白症。 患有肝损伤可能是在风险增加的毒性，因为增加了次要代谢途径的活动。 同样地，慢性或过度使用的醋氨酚可能饱和的主肝酶和导致增加的新陈代谢通过次要的途径。 严重的肝脏损伤，包括情况下的急性肝衰竭导致肝脏移植手术而死亡，已报道的患者使用的醋氨酚。 治疗与对乙酰氨基酚应给予谨慎的患者的肝脏功能不全。 临床监测的肝功能的建议。 指导患者，以避免喝酒，同时把对乙酰氨基酚含的药物。 患者应该被警告不得超过建议的最高总的每日剂量的醋氨酚(4克/天的成人和儿童12岁或以上)，并来读取所有的处方并非处方药物的标签，以确保他们不把多对乙酰氨基酚含的产品，或检查与医疗保健专业人员，如果他们不能确定。

来源
  • Gillette JR "An integrated approach to the study of chemically reactive metabolites of acetaminophen." Arch Intern Med 141 (1981): 375-9
  • Arnman R, Olsson R "Elimination of paracetamol in chronic liver disease." Acta Hepatogastroenterol (Stuttg) 25 (1978): 283-6
  • Clements JA, Critchley JA, Prescott LF "The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man." Br J Clin Pharmacol 18 (1984): 481-5
  • Forrest JA, Adriaenssens P, Finlayson ND, Prescott LF "Paracetamol metabolism in chronic liver disease." Eur J Clin Pharmacol 15 (1979): 427-31
  • Venkataramanan R, Kalp K, Rabinovitch M, et al "Conjugative drug metabolism in liver transplant patients." Transplant Proc 21 (1989): 2455
  • "Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical, Raritan, NJ.
Acetaminophen and Codeine Oral Solution

非专利名称: acetaminophen / codeine

品牌: Tylenol with Codeine #3, Tylenol with Codeine #4, EZ III, Phenaphen with Codeine, Tylenol with Codeine, Capital and Codeine Suspension, Tylenol with Codeine #2, Vopac, Cocet, Cocet Plus, Capital w/Codeine, Tylenol w/ Codeine

同义词: Acetaminophen and codeine, Acetaminophen and Codeine

Acetaminophen and Codeine Oral Solution是什么？
其他的药物 删除
Acetaminophen and Codeine Oral Solution <> 肝病
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

麻醉(阿片)的止痛剂是广泛代谢通过的肝脏，他们(例如，可待因酮、哌替啶、美沙酮、吗啡、右丙氧芬)有活动的代谢产物，是进一步转换到活性物质。 血清中浓度的这些药物及其代谢物可能增加和半衰期的延长患者受损的肝功能。 治疗阿片类物质，应给予谨慎，并开始在减少剂量的患者的肝脏疾病。 随后的剂量应该滴定基于个人的响应，而不是一种固定剂量时间表。

来源
  • "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.
  • "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.
  • "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.
  • "Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company, Vernon Hills, IL.
  • "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.
  • Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992): 467-74
  • "Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company, Whippany, NJ.
  • Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991): 635-42
  • McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980): 106-14
  • "Product Information. Calcidrine (codeine)." Abbott Pharmaceutical, Abbott Park, IL.
  • Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989): 463-9
  • Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982): 1267-70
  • Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978): 488-93
  • "Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  • "Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company, Whippany, NJ.
  • "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  • Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996): 812-20
  • Gram LF, Schou J, Way WL, et al "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979): 473-82
  • "Product Information. Numorphan (oxymorphone)" Endo Laboratories LLC, Chadds Ford, PA.
  • Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990): 289-97
  • "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.
  • Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979): 96-102
  • Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992): 487-95
  • Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993): 463-72
  • Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991): 1-23
  • "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.
  • "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.
  • "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.
  • Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995): 619-23
  • Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979): 314-7
  • McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974): 281-7
  • Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983): 3-17
  • "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.
  • Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984): 73-7
  • Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968): 754-62
  • "Product Information. Opium Tincture (opium)" Lilly, Eli and Company, Indianapolis, IN.
  • Pond SM, Tong T, Benowitz NL, et al "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981): 183-8
  • Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993): 344-54
  • "Product Information. Darvon (propoxyphene)." Lilly, Eli and Company, Indianapolis, IN.
  • Novick DM, Kreek MJ, Arns PA, et al "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985): 349
  • "Product Information. Alfenta (alfentanil)." Janssen Pharmaceutica, Titusville, NJ.
  • Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980): 417-24
  • Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987): 293-8
  • "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.
  • "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.
  • Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992): 479-84
  • Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990): 12-9
  • Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993): 893-903
  • Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992): 617-21
  • Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991): 381-90
  • Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972): 244
  • Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995): 37-44
  • Kreek MJ, Fanizza AM, et al "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981): 353-62
  • Parab PV, Ritschel WA, Coyle DE, et al "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988): 187-99
  • Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991): 330-6
  • Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991): 516-8
  • Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992): 462-5
  • "Product Information. Dalgan (dezocine)." Astra USA, Westborough, MA.
Acetaminophen and Codeine Oral Solution

非专利名称: acetaminophen / codeine

品牌: Tylenol with Codeine #3, Tylenol with Codeine #4, EZ III, Phenaphen with Codeine, Tylenol with Codeine, Capital and Codeine Suspension, Tylenol with Codeine #2, Vopac, Cocet, Cocet Plus, Capital w/Codeine, Tylenol w/ Codeine

同义词: Acetaminophen and codeine, Acetaminophen and Codeine

Acetaminophen and Codeine Oral Solution是什么？
其他的药物 删除
公认药物相互作用的清单
DiseDoc 和平
与食物，生活方式相互作用
  1. Acetaminophen and Codeine Oral Solution
药物互相作用
  1. Acetaminophen and Codeine Oral Solution
我们使用Cookie来优化网站性能。通过继续浏览这个网站,你同意使用Cookie。 同意